These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32263770)

  • 41. Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer.
    Ortiz R; Cabeza L; Arias JL; Melguizo C; Álvarez PJ; Vélez C; Clares B; Áranega A; Prados J
    AAPS J; 2015 Jul; 17(4):918-29. PubMed ID: 25894746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Incidence and survival of colorectal carcinoma among permanent residents in Yangpu district of Shanghai, from 2002 to 2012].
    Han X; Huang C; Zhao J; Ding Y; Zhang H; Cao G
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):289-94. PubMed ID: 24831629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Preoperative Peripheral Blood Monocyte Count Is Associated with Liver Metastasis and Overall Survival in Colorectal Cancer Patients.
    Hu S; Zou Z; Li H; Zou G; Li Z; Xu J; Wang L; Du X
    PLoS One; 2016; 11(6):e0157486. PubMed ID: 27355390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.
    Buskermolen M; Gini A; Naber SK; Toes-Zoutendijk E; de Koning HJ; Lansdorp-Vogelaar I
    Med Decis Making; 2018 Nov; 38(8):917-929. PubMed ID: 30343626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potentials of polymeric nanoparticle as drug carrier for cancer therapy: with a special reference to pharmacokinetic parameters.
    Mukherjee B; Das S; Chakraborty S; Satapathy BS; Das PJ; Mondal L; Hossain CM; Dey NS; Chaudhury A
    Curr Drug Metab; 2014; 15(6):565-80. PubMed ID: 24909417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of factors predictive of postoperative morbidity and short-term mortality in older patients after colorectal carcinoma resection: A single-center retrospective study.
    Schreckenbach T; Zeller MV; El Youzouri H; Bechstein WO; Woeste G
    J Geriatr Oncol; 2018 Nov; 9(6):649-658. PubMed ID: 29779798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Wingless signaling pathway family relation to colon cancer. Have we come full circle?
    Al-Kuraya KS; Bhatia KG
    Saudi Med J; 2005 Jan; 26(1):19-23. PubMed ID: 15756347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition.
    Al-Qasem A; Al-Howail HA; Al-Swailem M; Al-Mazrou A; Al-Otaibi B; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
    Mol Carcinog; 2016 Mar; 55(3):233-44. PubMed ID: 25641341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects.
    Li Y; Thambi T; Lee DS
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28941203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of cadherin-17 in human colon cancer LIM1215 cell secretome and tumour xenograft-derived interstitial fluid and plasma.
    Bernhard OK; Greening DW; Barnes TW; Ji H; Simpson RJ
    Biochim Biophys Acta; 2013 Nov; 1834(11):2372-9. PubMed ID: 23557862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives.
    Zhang J; Wang L; You X; Xian T; Wu J; Pang J
    Curr Top Med Chem; 2019; 19(1):57-73. PubMed ID: 30686255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives.
    Aghabozorgi AS; Bahreyni A; Soleimani A; Bahrami A; Khazaei M; Ferns GA; Avan A; Hassanian SM
    Biochimie; 2019 Feb; 157():64-71. PubMed ID: 30414835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment.
    Anitha A; Deepa N; Chennazhi KP; Lakshmanan VK; Jayakumar R
    Biochim Biophys Acta; 2014 Sep; 1840(9):2730-43. PubMed ID: 24946270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemoprevention of colorectal cancer: ready for routine use?
    Arber N; Levin B
    Recent Results Cancer Res; 2005; 166():213-30. PubMed ID: 15648192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.
    Deshmukh R; Prajapati M; Harwansh RK
    Curr Pharm Biotechnol; 2024; 25(5):599-622. PubMed ID: 38807329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymeric Nanoparticles for Drug Delivery.
    Beach MA; Nayanathara U; Gao Y; Zhang C; Xiong Y; Wang Y; Such GK
    Chem Rev; 2024 May; 124(9):5505-5616. PubMed ID: 38626459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.
    Yu X; Zhu L
    Int J Nanomedicine; 2024; 19():1867-1886. PubMed ID: 38414525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. pH-Sensitive Acrylic Terpolymers for the Coating of Orally Administered Drugs Used for Colonic Release.
    Suárez LM; Hoyos L; Castellote-Borrell M; Guasch J; Orozco VH; Giraldo LF
    ACS Omega; 2024 Jan; 9(1):204-214. PubMed ID: 38222599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.
    Chehelgerdi M; Chehelgerdi M; Allela OQB; Pecho RDC; Jayasankar N; Rao DP; Thamaraikani T; Vasanthan M; Viktor P; Lakshmaiya N; Saadh MJ; Amajd A; Abo-Zaid MA; Castillo-Acobo RY; Ismail AH; Amin AH; Akhavan-Sigari R
    Mol Cancer; 2023 Oct; 22(1):169. PubMed ID: 37814270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.